LONDON (Reuters) – Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy, according to a www.clinicaltrials.gov entry. This study is not the new trial planned by the company after late-stage trial results last month, which wiped as much as $125 billion off […]
Health
Novo Nordisk will test CagriSema’s long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
Audio By Carbonatix
LONDON (Reuters) – Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy, according to a www.clinicaltrials.gov entry.
This study is not the new trial planned by the company after late-stage trial results last month, which wiped as much as $125 billion off its market value. It said then that it would initiate a new trial in 2025 but did not say when exactly.
The long-term efficacy trial is estimated to end in November 2028, the entry shows. The company did not immediately respond to a request to comment.
(This story has been corrected to say that the trial is to test long-term efficacy, not the late-stage CagriSema trial planned after data in December, in headline and paragraphs 1 and 2)
(Reporting by Maggie Fick; Editing by Ros Russell and David Goodman)